Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition
Yuliya Lytvyn(University Health Network), David Z.I. Cherney(University Health Network), Nima Soleymanlou(Boehringer Ingelheim (Canada)), Karen Kimura(Boehringer Ingelheim (Canada)), Leslie Cham(University Health Network), Vesta Lai(University Health Network), Bruce A. Perkins(Sinai Health System), Nuala Peter(Thrombosis Research Institute), Josephine Tse(University Health Network)
Cited by 69
Related Papers
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
|The Lancet|2022|1k
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
|Circulation|2013|930
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
|Circulation|2017|470
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
|Nephrology Dialysis Transplantation|2019|216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
|Nephrology Dialysis Transplantation|2020|189